Pumitamig Alone or With Ipilimumab for Liver Cancer
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 198 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
This trial is looking for people with advanced liver cancer who have not received treatment before. Participants will take Pumitamig by itself or with another drug called Ipilimumab to see how safe it is.
You may be able to join if
- I have been diagnosed with liver cancer that cannot be removed by surgery.
- I have a performance status of 0 or 1.
- I have not had previous treatment for advanced liver cancer.
- I have measurable cancer according to specific medical criteria.
You may not be able to join if
- I have significant bleeding or clotting disorders.
- I have had an organ transplant.
- I have an autoimmune disease.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Loading trial locations…
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT